Genmab — August 2019
-
@EL regarding the Nature Letter: 3 patients with ALL
received intensive chemotherapy for a third or fourth early relapse, achieved remission but remained MRD+. At that point, all of them were treated with daratumumab at doses and schedules identical to the myeloma protocol and achieved MRD− remission after 3–4 doses of induction. All the patients are currently alive and in MRD− remission for 44, 43, and 5 weeks, respectively. -
In these three heavily pretreated ALL patients (Table 1), administration of daratumumab was not associated with any significant immediate side effects....This novel approach may bring new hope to patients with a devastating disease such as relapsed ALL
-
Result //
In the EGFR WT/ALK- cohort, 26 patients (median age 65.5 years, range 38–74; 57.7% male) with ECOG PS of 0 (11.5%) or 1 (88.5%) have been enrolled. Most patients (23/26) were treated with a checkpoint inhibitor. At a median follow-up of 18 weeks (range: 2–54), the most common (≥20%; any grade) treatment-emergent adverse events (TEAEs) were fatigue, constipation, nausea, decreased appetite, decreased weight, diarrhea, and vomiting. Two patients had a TEAE leading to dose reduction. -
Grade ≥3 TEAEs occurred in 12 patients, with the most common being gastrointestinal disorders in eight patients (constipation [n=1]; colitis, diarrhea, nausea, vomiting [n=2 each]; abdominal distension [n=1]. The confirmed ORR is 19% (95% CI: 8.5%, 37.9%). The disease control rate (CR+PR+SD) is 50% (13/26). Nine of 12 (75%) evaluable fresh biopsies were positive for AXL tumor cell staining.
-
Conclusion //
In this high unmet need patient population, with advanced EGFR WT and ALK- NSCLC who are pretreated with PD-1/PD-L1 inhibitors and platimum-based therapies, EnaV monotherapy demonstrated a manageable safety profile and encouraging preliminary clinical activity. This cohort has expanded to allow up to 60 patients to gain further knowledge of AXL as a potential biomarker for responsiveness to EnaV and to gather additional data on safety and efficacy. -
Linket til selve siden kan ikke pastes direkte, men her i to bidder: "https://library.iaslc.org/conference-program?"
-
Well, det kan åbenbart ikke lade sige gøre. Linket findes sidste i afsnittet "Enapotamab vedotin abstract to be presented" i GENs pressemedd. https://ir.genmab.com/news-releases/news-release-details/genmab-announces-preliminary-data-be-presented-iaslc-2019-world
-
er der nogen, der har styr på, hvor meget stable disease betyder ifht AXL behandlingen i den her population?
-
ORR er noget underwhelming for mig, mens der ligger en del i SD "responsen"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind